Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations

Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) carriers and also in HBs Ag-negative patients who have resolved HBV infection. The p...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 21; no. 36; pp. 10274 - 10289
Main Author Mori, Shunsuke
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.09.2015
Subjects
Antirheumatic Agents - adverse effects
Antiviral Agents - therapeutic use
Hepatitis
Hepatitis B - diagnosis
Hepatitis B - epidemiology
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Humans
Immunocompromised Host
Prevalence
Recurrence
Rheumatic Diseases - diagnosis
Rheumatic Diseases - drug therapy
Rheumatic Diseases - epidemiology
Rheumatic Diseases - immunology
Risk Assessment
Risk Factors
therapy;Resolved
Topic Highlight
Virus Activation - drug effects
virus;Antirheumatic
Reactivation
Resolved hepatitis B virus infection
Hepatitis B virus
Occult hepatitis B virus carrier
Antirheumatic therapy
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v21.i36.10274

Cover

Abstract Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) carriers and also in HBs Ag-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients,ranging from 7.3% to 66%. Through an electronic search of the Pub Med database,we found that among 712 patients with resolved infection in 17 observational cohort studies,12 experienced HBV reactivation(1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy,0.6% for adalimumab,0% for infliximab,8.6% for tocilizumab,and 3.3% for rituximab. Regarding non-biological antirheumatic drugs,HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies(3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established,but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields,rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
AbstractList Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients, ranging from 7.3% to 66%. Through an electronic search of the PubMed database, we found that among 712 patients with resolved infection in 17 observational cohort studies, 12 experienced HBV reactivation (1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy, 0.6% for adalimumab, 0% for infliximab, 8.6% for tocilizumab, and 3.3% for rituximab. Regarding non-biological antirheumatic drugs, HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies (3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established, but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields, rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients, ranging from 7.3% to 66%. Through an electronic search of the PubMed database, we found that among 712 patients with resolved infection in 17 observational cohort studies, 12 experienced HBV reactivation (1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy, 0.6% for adalimumab, 0% for infliximab, 8.6% for tocilizumab, and 3.3% for rituximab. Regarding non-biological antirheumatic drugs, HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies (3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established, but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields, rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients, ranging from 7.3% to 66%. Through an electronic search of the PubMed database, we found that among 712 patients with resolved infection in 17 observational cohort studies, 12 experienced HBV reactivation (1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy, 0.6% for adalimumab, 0% for infliximab, 8.6% for tocilizumab, and 3.3% for rituximab. Regarding non-biological antirheumatic drugs, HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies (3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established, but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields, rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) carriers and also in HBs Ag-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients,ranging from 7.3% to 66%. Through an electronic search of the Pub Med database,we found that among 712 patients with resolved infection in 17 observational cohort studies,12 experienced HBV reactivation(1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy,0.6% for adalimumab,0% for infliximab,8.6% for tocilizumab,and 3.3% for rituximab. Regarding non-biological antirheumatic drugs,HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies(3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established,but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields,rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
Author Shunsuke Mori Shigetoshi Fujiyama
AuthorAffiliation Department of Rheumatology,Clinical Research Center for Rheumatic Diseases,NHO Kumamoto Saishunsou National Hospital Department of Hepatology and Gastroenterology,Kumamoto Shinto General Hospital
Author_xml – sequence: 1
  givenname: Shunsuke
  surname: Mori
  fullname: Mori, Shunsuke
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26420955$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1vFCEYJqam3db-AC9mjl5m5XMADybaVGvSxIueCcswO6wzMAVm6_77stt1ox6EA4Tni7zPJTjzwVsAXiO4JJyKd4-b9XKL0dKRZokg5vQFWGCMZI0FhWdggSDktSSYX4DLlDYQYkIYPgcXuKEYSsYWYHNnJ51ddqn6VG1dnFMVrTbZbctr8JVOKRins22rR5f7SvvsYm_nscCmyr2Netq9r6JLPwvWVlMMU78b9C-3NzJhHK1vD1bpFXjZ6SHZ6-N5BX58vv1-c1fff_vy9ebjfW0oJblGhGhuBdEY6xYT2xnYWQtRC5tuBY2WZTdIGKp5y2UDEdMroQ0jK2IgI5JcgQ_PvtO8Gm1rrM9RD2qKbtRxp4J26m_Eu16tw1ZRxqXgrBi8PRrE8DDblNXokrHDoL0Nc1KII0EIlLIp1Dd_Zp1Cfg-4ENAzwcSQUrTdiYKg2peoSomqlKhKiepQYtHwfzTG5cMMy3fd8F8lOSr74NcPzq9PcRKK_ZIMUkElIwwxWm6CYfIEjsq2YQ
CitedBy_id crossref_primary_10_1111_jvh_13060
crossref_primary_10_14412_1996_7012_2019_4_79_83
crossref_primary_10_6004_jnccn_2019_0013
crossref_primary_10_2174_18742203_v10_e230719_2022_49
crossref_primary_10_1111_1346_8138_14096
crossref_primary_10_1128_CMR_00035_19
crossref_primary_10_1007_s10067_018_4096_0
crossref_primary_10_1590_0037_8682_0386_2018
crossref_primary_10_33667_2078_5631_2023_9_17_24
crossref_primary_10_1371_journal_pbio_3000286
crossref_primary_10_4274_tod_galenos_2024_69783
crossref_primary_10_1016_j_rgmx_2021_04_002
crossref_primary_10_3349_ymj_2018_59_3_452
crossref_primary_10_1111_1756_185X_14034
crossref_primary_10_1136_rmdopen_2020_001171
crossref_primary_10_1007_s40257_021_00603_w
crossref_primary_10_3390_pathogens11070816
crossref_primary_10_1093_rheumatology_key208
crossref_primary_10_1097_BOR_0000000000000281
crossref_primary_10_1007_s10067_020_05345_4
crossref_primary_10_33715_inonusaglik_1467613
crossref_primary_10_1016_j_berh_2019_03_008
crossref_primary_10_1016_j_jaad_2017_01_037
crossref_primary_10_1016_j_idc_2020_02_003
crossref_primary_10_1016_j_rdc_2016_09_003
crossref_primary_10_1002_hep_29800
crossref_primary_10_1016_j_idc_2020_02_009
crossref_primary_10_14412_1995_4484_2020_31_36
crossref_primary_10_1111_aji_13083
crossref_primary_10_3748_wjg_v28_i23_2527
crossref_primary_10_1007_s00432_022_04133_8
crossref_primary_10_3390_jcm13010015
crossref_primary_10_3390_microorganisms8111792
crossref_primary_10_1080_14760584_2016_1193438
crossref_primary_10_12659_AJCR_896496
crossref_primary_10_1111_cen3_12721
crossref_primary_10_1016_j_cgh_2018_04_033
crossref_primary_10_1016_j_jcjq_2018_12_003
crossref_primary_10_2147_OARRR_S246246
crossref_primary_10_1007_s10900_022_01111_6
crossref_primary_10_1016_j_gtc_2019_02_006
crossref_primary_10_1039_D1SC01748A
crossref_primary_10_1111_iju_14218
crossref_primary_10_1016_j_micpath_2017_12_014
crossref_primary_10_1007_s44178_023_00061_w
crossref_primary_10_1111_1756_185X_14217
crossref_primary_10_1093_ibd_izx001
crossref_primary_10_3390_jcm10215201
crossref_primary_10_1016_j_rdc_2016_09_012
crossref_primary_10_1136_jitc_2020_000943
crossref_primary_10_3390_livers3030026
crossref_primary_10_1080_14740338_2023_2181339
crossref_primary_10_2217_imt_2018_0113
crossref_primary_10_1007_s40257_019_00457_3
crossref_primary_10_1080_03009742_2020_1744712
crossref_primary_10_1016_j_heliyon_2024_e41444
crossref_primary_10_5217_ir_2019_09155
crossref_primary_10_1080_14397595_2017_1419842
crossref_primary_10_1007_s00296_018_4021_5
crossref_primary_10_1136_rmdopen_2019_001095
crossref_primary_10_33667_2078_5631_2019_1_18_393__39_43
crossref_primary_10_1590_1806_9282_20240091
crossref_primary_10_12677_ACM_2021_1111736
crossref_primary_10_1586_17512433_2016_1143773
crossref_primary_10_1080_09546634_2018_1543843
crossref_primary_10_1016_j_rgmxen_2021_04_002
crossref_primary_10_1038_s41598_020_59406_4
crossref_primary_10_1371_journal_pone_0154744
crossref_primary_10_1111_1756_185X_14125
crossref_primary_10_1155_2018_5217461
crossref_primary_10_1111_1756_185X_13752
crossref_primary_10_1111_1346_8138_15244
crossref_primary_10_1007_s11938_019_00236_3
Cites_doi 10.1055/s-0033-1345722
10.1159/000076640
10.1046/j.1537-2995.2003.00391.x
10.1182/blood-2002-03-0798
10.3899/jrheum.120052
10.1016/j.ejim.2013.11.014
10.1093/rheumatology/ken384
10.1097/MEG.0b013e3283329d13
10.1517/14712598.2011.554810
10.1002/hep.510270638
10.1007/s10165-011-0521-9
10.1016/0016-5085(91)90599-G
10.1186/1471-2474-15-449
10.1016/j.semarthrit.2007.10.011
10.1007/s10165-011-0458-z
10.1016/j.jhep.2005.01.018
10.1002/hep.27716
10.1097/MD.0b013e3182380a76
10.1111/j.1478-3231.2010.02238.x
10.1186/ar2868
10.1200/JCO.2008.18.0182
10.1002/ddr.21193
10.1073/pnas.95.24.14447
10.1136/jcp.46.4.304
10.3899/jrheum.110289
10.7326/0003-4819-112-5-381
10.1007/s10165-011-0470-3
10.1007/s10067-012-1960-1
10.1002/hep.20956
10.1002/hep.22945
10.1056/NEJMp068087
10.1016/j.jhep.2008.07.014
10.1093/rheumatology/ken362
10.1073/pnas.97.16.9203
10.1111/j.1445-5994.2007.01479.x
10.1007/s10067-012-1988-2
10.2450/2012.0160-12
10.1016/j.jbspin.2011.07.003
10.1016/j.jbspin.2011.05.017
10.1002/hep.21529
10.1053/jhep.2000.8541
10.1136/ard.2011.151027
10.1200/JCO.2010.29.7531
10.3109/14397595.2013.852834
10.1016/S1473-3099(02)00345-6
10.1056/NEJM200101043440120
10.3899/jrheum.081246
10.1002/jmv.21734
10.1002/acr.20130
10.1073/pnas.91.9.3764
10.1053/j.gastro.2006.04.015
10.3899/jrheum.090436
10.1016/j.jinf.2006.02.002
10.1007/s10067-010-1438-y
10.4254/wjh.v5.i7.387
10.1073/pnas.83.6.1627
10.1007/s12185-009-0359-5
10.1002/hep.22882
10.1016/S1074-7613(00)80295-2
10.3899/jrheum.100692
10.1056/NEJM199907013410104
10.1155/2014/926836
10.1111/j.1478-3231.2007.01665.x
10.1093/rheumatology/ket221
10.1007/s10067-006-0392-1
10.1016/j.ejim.2011.09.001
10.1111/j.1365-2133.2007.08058.x
10.1002/hep.22841
10.1016/j.patbio.2010.02.003
10.1016/j.vaccine.2011.12.116
10.1046/j.1537-2995.2001.41091093.x
10.1016/j.jhep.2006.10.007
10.1163/156855900300109152
10.1136/ard.2009.127233
10.1016/j.coi.2010.12.013
10.1159/000338143
10.4065/82.8.967
10.1136/annrheumdis-2012-202088
10.5365/WPSAR.2011.2.1.008
10.1007/s10067-010-1523-2
10.1016/j.jbspin.2006.11.020
10.1136/ard.2010.148783
10.1002/art.23721
10.3899/jrheum.081324
10.1007/s10165-010-0337-z
10.1007/s10067-013-2385-1
10.1111/hepr.12269
10.1016/j.jbspin.2008.11.005
10.1111/1756-185X.12359
10.1093/annonc/mdp230
10.1007/s10165-010-0365-8
10.1007/s10067-013-2450-9
10.1097/RHU.0b013e318181b89d
10.1128/JVI.77.4.2469-2476.2003
10.1136/bcr.09.2008.0873
10.1155/2013/410521
10.1007/s10067-008-0896-y
10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q
10.1111/j.1872-034X.2012.00998.x
10.1007/s00535-010-0367-5
10.3324/haematol.11224
10.1136/ard.62.7.686
10.1016/j.jhep.2011.10.011
10.1002/hep.22976
10.1007/s00296-009-1202-2
10.1007/s00277-009-0806-7
10.1002/acr.21654
10.1111/j.1365-2141.2010.08076.x
10.1371/journal.pone.0092266
10.1136/ard.2009.126532
10.1055/s-2005-915644
10.1038/nm1096-1104
10.1136/annrheumdis-2011-200350
10.1111/j.1537-2995.2010.03056.x
10.1016/j.jhep.2008.01.023
10.1111/1756-185X.12154
10.1002/hep.23327
10.1086/590968
10.1002/hep.21513
10.1002/hep.510310232
10.1111/j.1346-8138.2011.01434.x
10.4049/jimmunol.180.2.688
10.1517/14740338.4.3.599
10.2169/internalmedicine.37.519
10.1016/j.jcv.2004.02.013
ContentType Journal Article
Copyright The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015
Copyright_xml – notice: The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v21.i36.10274
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations
EISSN 2219-2840
EndPage 10289
ExternalDocumentID PMC4579875
26420955
10_3748_wjg_v21_i36_10274
90888889504849535154484852
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c443t-133a7e83a22ad23efc0fee01d06fb0ca9a9a618c4a7d796015ab8ac53b3c05393
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 14:32:03 EDT 2025
Fri Jul 11 04:29:03 EDT 2025
Mon Jul 21 06:03:24 EDT 2025
Tue Jul 01 01:53:57 EDT 2025
Thu Apr 24 22:52:59 EDT 2025
Wed Feb 14 10:21:13 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 36
Keywords Reactivation
Resolved hepatitis B virus infection
Hepatitis B virus
Occult hepatitis B virus carrier
Antirheumatic therapy
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c443t-133a7e83a22ad23efc0fee01d06fb0ca9a9a618c4a7d796015ab8ac53b3c05393
Notes Shunsuke Mori;Shigetoshi Fujiyama;Department of Rheumatology,Clinical Research Center for Rheumatic Diseases,NHO Kumamoto Saishunsou National Hospital;Department of Hepatology and Gastroenterology,Kumamoto Shinto General Hospital
Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been reported in inactive hepatitis B surface antigen(HBs Ag) carriers and also in HBs Ag-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients,ranging from 7.3% to 66%. Through an electronic search of the Pub Med database,we found that among 712 patients with resolved infection in 17 observational cohort studies,12 experienced HBV reactivation(1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy,0.6% for adalimumab,0% for infliximab,8.6% for tocilizumab,and 3.3% for rituximab. Regarding non-biological antirheumatic drugs,HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies(3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established,but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields,rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
Hepatitis B virus;Antirheumatic therapy;Resolved h
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Correspondence to: Shunsuke Mori, MD, PhD, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, 2659 Suya, Kohshi, Kumamoto 861-1196, Japan. moris@saisyunsou1.hosp.go.jp
Author contributions: All authors contributed to the study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript and making critical revisions with regard to important intellectual content, and final approval of the manuscript.
Telephone: +81-96-2421000 Fax: +81-96-2422619
OpenAccessLink https://www.wjgnet.com/1007-9327/full/v21/i36/10274.htm
PMID 26420955
PQID 1718330996
PQPubID 23479
PageCount 16
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4579875
proquest_miscellaneous_1718330996
pubmed_primary_26420955
crossref_primary_10_3748_wjg_v21_i36_10274
crossref_citationtrail_10_3748_wjg_v21_i36_10274
chongqing_primary_90888889504849535154484852
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-09-28
PublicationDateYYYYMMDD 2015-09-28
PublicationDate_xml – month: 09
  year: 2015
  text: 2015-09-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2015
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References ref57
ref56
ref59
ref58
ref53
ref52
ref55
ref54
ref51
ref50
ref46
ref45
ref48
ref47
ref42
ref41
ref44
ref43
ref49
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref100
ref101
ref40
ref35
ref34
ref37
ref36
ref31
ref30
ref33
ref32
ref39
ref38
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref13
ref12
ref15
ref128
ref14
ref129
ref97
ref126
ref96
ref127
ref11
ref99
ref124
ref10
ref98
ref125
ref17
ref16
ref19
ref18
ref93
ref133
ref92
ref134
ref95
ref131
ref94
ref132
ref130
ref91
ref90
ref89
ref86
ref85
ref88
ref135
ref87
ref82
ref81
ref84
ref83
ref80
ref79
ref108
ref78
ref109
ref106
ref107
ref75
ref104
ref74
ref105
ref77
ref102
ref76
ref103
ref2
ref1
ref71
ref111
ref70
ref112
ref73
ref72
ref110
ref68
ref119
ref67
ref117
ref69
ref118
ref64
ref115
ref63
ref116
ref66
ref113
ref65
ref114
ref60
ref122
ref123
ref62
ref120
ref61
ref121
19075267 - J Clin Oncol. 2009 Feb 1;27(4):605-11
20303674 - Pathol Biol (Paris). 2010 Aug;58(4):254-7
16908487 - N Engl J Med. 2006 Sep 7;355(10):973-5
15044834 - Intervirology. 2004;47(1):32-40
19399812 - Hepatology. 2009 May;49(5 Suppl):S35-44
11229464 - Arthritis Rheum. 2001 Feb;44(2):339-42
25114684 - Int J Rheumatol. 2014;2014:926836
19399803 - Hepatology. 2009 May;49(5 Suppl):S156-65
21269234 - Expert Opin Biol Ther. 2011 Apr;11(4):533-44
8574849 - Immunity. 1996 Jan;4(1):25-36
21686590 - BMJ Case Rep. 2009;2009:null
9678685 - Intern Med. 1998 Jun;37(6):519-22
25532827 - BMC Musculoskelet Disord. 2014;15:449
15885351 - J Hepatol. 2005 Jun;42(6):813-9
19797507 - J Rheumatol. 2009 Nov;36(11):2416-20
21626075 - Mod Rheumatol. 2011 Dec;21(6):701-5
25381975 - Drug Dev Res. 2014 Nov;75 Suppl 1:S42-5
22077677 - J Dermatol. 2012 Mar;39(3):269-73
16103976 - Semin Liver Dis. 2005;25 Suppl 1:3-8
22935442 - Clin Exp Rheumatol. 2013 Jan-Feb;31(1):25-30
10922071 - Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9203-8
22033451 - Medicine (Baltimore). 2011 Nov;90(6):359-71
19561036 - Ann Oncol. 2009 Dec;20(12):2013-7
10655275 - Hepatology. 2000 Feb;31(2):488-95
9826720 - Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14447-52
11187122 - N Engl J Med. 2001 Jan 4;344(1):68-9
20472596 - Ann Rheum Dis. 2010 Jul;69(7):1352-5
24698305 - Int J Rheum Dis. 2016 May;19(5):470-5
17644391 - Joint Bone Spine. 2007 Oct;74(5):407-9
16831590 - Gastroenterology. 2006 Jul;131(1):59-68
18178805 - J Immunol. 2008 Jan 15;180(2):688-92
21528424 - Mod Rheumatol. 2011 Dec;21(6):621-7
18512708 - Arthritis Rheum. 2008 Jun 15;59(6):762-84
21196589 - J Rheumatol. 2011 Jan;38(1):181-2
12757519 - Transfusion. 2003 Jun;43(6):696-704
19544079 - Int J Hematol. 2009 Jul;90(1):13-23
17112622 - J Hepatol. 2007 Jan;46(1):160-70
1962626 - Am J Gastroenterol. 1991 Dec;86(12):1804-8
18221983 - Semin Arthritis Rheum. 2008 Dec;38(3):208-17
24077913 - Clin Rheumatol. 2014 Jan;33(1):119-23
11128108 - Haematologia (Budap). 2000;30(3):159-65
23606869 - Clin Dev Immunol. 2013;2013:410521
20166185 - J Med Virol. 2010 Apr;82(4):546-55
18173926 - Clin Exp Rheumatol. 2007 Nov-Dec;25(6):888-9
24261752 - Mod Rheumatol. 2014 Jan;24(1):1-7
17673066 - Mayo Clin Proc. 2007 Aug;82(8):967-75
22127282 - J Hepatol. 2012 Jun;56(6):1420-1
20444750 - Ann Rheum Dis. 2010 Jun;69(6):964-75
25613809 - Hepatology. 2015 Jul;62(1):40-6
20345703 - Liver Int. 2010 Sep;30(8):1241-2
11552064 - Transfusion. 2001 Sep;41(9):1093-9
23771951 - Rheumatology (Oxford). 2014 Jan;53(1):195-6
20306568 - Eur J Gastroenterol Hepatol. 2010 Apr;22(4):494-9
15934864 - Expert Opin Drug Saf. 2005 May;4(3):599-608
20556450 - Clin Rheumatol. 2010 Sep;29(9):1021-9
18433400 - Liver Int. 2008 May;28(5):718-20
9779869 - J Rheumatol. 1998 Oct;25(10):2037-8
15288614 - J Clin Virol. 2004 Sep;31(1):53-7
20049753 - Hepatology. 2010 Feb;51(2):422-30
22796807 - Dig Dis. 2012;30(4):408-14
23935355 - Hippokratia. 2013 Jan;17(1):91-3
17256718 - Hepatology. 2007 Feb;45(2):507-39
20931272 - Mod Rheumatol. 2011 Apr;21(2):215-8
21953336 - Ann Rheum Dis. 2012 Jan;71(1):4-12
18854348 - Rheumatology (Oxford). 2008 Dec;47(12):1838-40
19447932 - J Rheumatol. 2009 Jun;36(6):1188-94
21807545 - Joint Bone Spine. 2011 Dec;78(6):653-4
21880218 - J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):285-9
18786966 - Rheumatology (Oxford). 2008 Nov;47(11):1732-3
21944979 - Joint Bone Spine. 2012 Jan;79(1):100-1
24343455 - Clin Rheumatol. 2014 Apr;33(4):577-86
9620351 - Hepatology. 1998 Jun;27(6):1736-42
18055990 - Haematologica. 2007 Dec;92(12):1664-70
20379839 - Clin Rheumatol. 2013 Mar;32 Suppl 1:S47-9
20837949 - J Clin Oncol. 2010 Dec 1;28(34):5097-100
23111095 - Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21
17596145 - Br J Dermatol. 2007 Sep;157(3):587-90
23399361 - Blood Transfus. 2013 Apr;11(2):281-8
2306066 - Ann Intern Med. 1990 Mar 1;112(5):381-2
18766129 - J Clin Rheumatol. 2008 Aug;14(4):245-6
18203328 - J Rheumatol. 2008 Mar;35(3):421-4
21844146 - J Rheumatol. 2011 Oct;38(10):2209-14
21901356 - Mod Rheumatol. 2012 Jun;22(3):470-3
22392695 - Arthritis Care Res (Hoboken). 2012 Aug;64(8):1265-8
12858469 - J Rheumatol. 2003 Jul;30(7):1624-5
20668905 - Mod Rheumatol. 2011 Feb;21(1):16-23
22349880 - Clin Rheumatol. 2012 Jun;31(6):931-6
20008922 - J Rheumatol. 2010 Feb;37(2):346-50
16564573 - J Infect. 2007 Feb;54(2):185-91
8496385 - J Clin Pathol. 1993 Apr;46(4):304-8
21540199 - Ann Rheum Dis. 2011 Jun;70(6):896-904
12551985 - J Virol. 2003 Feb;77(4):2469-76
24164839 - Int J Rheum Dis. 2013 Oct;16(5):527-31
12810441 - Ann Rheum Dis. 2003 Jul;62(7):686-7
21257300 - Curr Opin Immunol. 2011 Apr;23(2):237-43
12239179 - Blood. 2002 Oct 1;100(7):2637-41
22686858 - Hepatol Res. 2012 Jul;42(7):627-36
21246383 - J Gastroenterol. 2011 Apr;46(4):556-64
24397839 - Hepatol Res. 2014 Jan;44 Suppl S1:1-58
22273662 - Vaccine. 2012 Mar 9;30(12):2212-9
19697028 - Ann Hematol. 2010 Mar;89(3):255-62
24495663 - Eur J Intern Med. 2014 Jun;25(5):482-4
15144137 - Clin Exp Rheumatol. 2004 May-Jun;22(3):375-6
3006059 - Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31
8170985 - Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8
22930597 - Ann Rheum Dis. 2013 Feb;72(2):308-10
19830433 - Rheumatol Int. 2011 Mar;31(3):403-4
18314221 - J Hepatol. 2008 May;48(5):743-6
20535784 - Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54
22544263 - Clin Rheumatol. 2012 Aug;31(8):1169-75
21719446 - Ann Rheum Dis. 2011 Oct;70(10):1719-25
22661417 - J Rheumatol. 2012 Jun;39(6):1292-3; author reply 1293
8837608 - Nat Med. 1996 Oct;2(10):1104-8
21332731 - Transfusion. 2011 Aug;51(8):1840-6
16865308 - Clin Rheumatol. 2007 Jun;26(6):950-2
20151975 - Br J Haematol. 2010 Apr;149(1):3-13
22075282 - Eur J Intern Med. 2011 Dec;22(6):572-5
1983820 - Gastroenterology. 1991 Jan;100(1):182-8
24663387 - PLoS One. 2014;9(3):e92266
19346146 - Joint Bone Spine. 2009 May;76(3):308-11
19941642 - Arthritis Res Ther. 2009;11(6):R179
19399815 - Hepatology. 2009 May;49(5 Suppl):S22-7
18521652 - Clin Rheumatol. 2008 Aug;27(8):1069-71
17894766 - Intern Med J. 2007 Oct;37(10):705-12
23908927 - Western Pac Surveill Response J. 2012 Aug 03;3(3):69-75
16447285 - Hepatology. 2006 Feb;43(2 Suppl 1):S173-81
19280622 - Hepatology. 2009 May;49(5):1503-14
23898372 - World J Hepatol. 2013 Jul 27;5(7):387-92
18643758 - Clin Infect Dis. 2008 Sep 1;47(5):e52-6
18715666 - J Hepatol. 2008 Oct;49(4):652-7
17256766 - Hepatology. 2007 Feb;45(2):277-85
23749673 - Semin Liver Dis. 2013 May;33(2):167-77
10869298 - Hepatology. 2000 Jul;32(1):116-23
12150847 - Lancet Infect Dis. 2002 Aug;2(8):479-86
10387938 - N Engl J Med. 1999 Jul 1;341(1):22-6
References_xml – ident: ref6
  doi: 10.1055/s-0033-1345722
– ident: ref2
  doi: 10.1159/000076640
– ident: ref33
  doi: 10.1046/j.1537-2995.2003.00391.x
– ident: ref32
  doi: 10.1182/blood-2002-03-0798
– ident: ref116
– ident: ref130
  doi: 10.3899/jrheum.120052
– ident: ref57
  doi: 10.1016/j.ejim.2013.11.014
– ident: ref105
  doi: 10.1093/rheumatology/ken384
– ident: ref96
  doi: 10.1097/MEG.0b013e3283329d13
– ident: ref102
  doi: 10.1517/14712598.2011.554810
– ident: ref16
  doi: 10.1002/hep.510270638
– ident: ref121
  doi: 10.1007/s10165-011-0521-9
– ident: ref22
  doi: 10.1016/0016-5085(91)90599-G
– ident: ref97
  doi: 10.1186/1471-2474-15-449
– ident: ref81
  doi: 10.1016/j.semarthrit.2007.10.011
– ident: ref51
  doi: 10.1007/s10165-011-0458-z
– ident: ref44
  doi: 10.1016/j.jhep.2005.01.018
– ident: ref113
– ident: ref60
  doi: 10.1002/hep.27716
– ident: ref98
  doi: 10.1097/MD.0b013e3182380a76
– ident: ref119
  doi: 10.1111/j.1478-3231.2010.02238.x
– ident: ref46
  doi: 10.1186/ar2868
– ident: ref9
  doi: 10.1200/JCO.2008.18.0182
– ident: ref58
  doi: 10.1002/ddr.21193
– ident: ref65
  doi: 10.1073/pnas.95.24.14447
– ident: ref41
  doi: 10.1136/jcp.46.4.304
– ident: ref52
  doi: 10.3899/jrheum.110289
– ident: ref67
  doi: 10.7326/0003-4819-112-5-381
– ident: ref103
  doi: 10.1007/s10165-011-0470-3
– ident: ref84
  doi: 10.1007/s10067-012-1960-1
– ident: ref3
  doi: 10.1002/hep.20956
– ident: ref5
  doi: 10.1002/hep.22945
– ident: ref106
  doi: 10.1056/NEJMp068087
– ident: ref28
  doi: 10.1016/j.jhep.2008.07.014
– ident: ref68
– ident: ref112
  doi: 10.1093/rheumatology/ken362
– ident: ref66
  doi: 10.1073/pnas.97.16.9203
– ident: ref134
  doi: 10.1111/j.1445-5994.2007.01479.x
– ident: ref54
  doi: 10.1007/s10067-012-1988-2
– ident: ref36
  doi: 10.2450/2012.0160-12
– ident: ref122
  doi: 10.1016/j.jbspin.2011.07.003
– ident: ref111
  doi: 10.1016/j.jbspin.2011.05.017
– ident: ref20
  doi: 10.1002/hep.21529
– ident: ref19
  doi: 10.1053/jhep.2000.8541
– ident: ref63
  doi: 10.1136/ard.2011.151027
– ident: ref12
  doi: 10.1200/JCO.2010.29.7531
– ident: ref133
  doi: 10.3109/14397595.2013.852834
– ident: ref55
– ident: ref13
  doi: 10.1016/S1473-3099(02)00345-6
– ident: ref7
  doi: 10.1056/NEJM200101043440120
– ident: ref94
  doi: 10.3899/jrheum.081246
– ident: ref35
  doi: 10.1002/jmv.21734
– ident: ref48
  doi: 10.1002/acr.20130
– ident: ref79
  doi: 10.1073/pnas.91.9.3764
– ident: ref8
  doi: 10.1053/j.gastro.2006.04.015
– ident: ref29
  doi: 10.3899/jrheum.090436
– ident: ref43
  doi: 10.1016/j.jinf.2006.02.002
– ident: ref95
  doi: 10.1007/s10067-010-1438-y
– ident: ref123
  doi: 10.4254/wjh.v5.i7.387
– ident: ref76
  doi: 10.1073/pnas.83.6.1627
– ident: ref24
  doi: 10.1007/s12185-009-0359-5
– ident: ref31
  doi: 10.1002/hep.22882
– ident: ref80
  doi: 10.1016/S1074-7613(00)80295-2
– ident: ref74
  doi: 10.3899/jrheum.100692
– ident: ref17
  doi: 10.1056/NEJM199907013410104
– ident: ref99
  doi: 10.1155/2014/926836
– ident: ref118
  doi: 10.1111/j.1478-3231.2007.01665.x
– ident: ref125
  doi: 10.1093/rheumatology/ket221
– ident: ref89
  doi: 10.1007/s10067-006-0392-1
– ident: ref127
  doi: 10.1016/j.ejim.2011.09.001
– ident: ref73
  doi: 10.1111/j.1365-2133.2007.08058.x
– ident: ref131
  doi: 10.1002/hep.22841
– ident: ref14
  doi: 10.1016/j.patbio.2010.02.003
– ident: ref1
  doi: 10.1016/j.vaccine.2011.12.116
– ident: ref45
  doi: 10.1046/j.1537-2995.2001.41091093.x
– ident: ref21
  doi: 10.1016/j.jhep.2006.10.007
– ident: ref39
  doi: 10.1163/156855900300109152
– ident: ref47
  doi: 10.1136/ard.2009.127233
– ident: ref128
  doi: 10.1016/j.coi.2010.12.013
– ident: ref135
  doi: 10.1159/000338143
– ident: ref4
  doi: 10.4065/82.8.967
– ident: ref115
  doi: 10.1136/annrheumdis-2012-202088
– ident: ref40
  doi: 10.5365/WPSAR.2011.2.1.008
– ident: ref77
  doi: 10.1007/s10067-010-1523-2
– ident: ref88
  doi: 10.1016/j.jbspin.2006.11.020
– ident: ref53
  doi: 10.1136/ard.2010.148783
– ident: ref61
  doi: 10.1002/art.23721
– ident: ref93
  doi: 10.3899/jrheum.081324
– ident: ref49
  doi: 10.1007/s10165-010-0337-z
– ident: ref56
  doi: 10.1007/s10067-013-2385-1
– ident: ref126
  doi: 10.1111/hepr.12269
– ident: ref82
  doi: 10.1016/j.jbspin.2008.11.005
– ident: ref86
– ident: ref117
– ident: ref59
  doi: 10.1111/1756-185X.12359
– ident: ref10
  doi: 10.1093/annonc/mdp230
– ident: ref104
  doi: 10.1007/s10165-010-0365-8
– ident: ref75
  doi: 10.1007/s10067-013-2450-9
– ident: ref91
  doi: 10.1097/RHU.0b013e318181b89d
– ident: ref78
  doi: 10.1128/JVI.77.4.2469-2476.2003
– ident: ref83
  doi: 10.1136/bcr.09.2008.0873
– ident: ref114
  doi: 10.1155/2013/410521
– ident: ref92
  doi: 10.1007/s10067-008-0896-y
– ident: ref69
  doi: 10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q
– ident: ref25
  doi: 10.1111/j.1872-034X.2012.00998.x
– ident: ref50
  doi: 10.1007/s00535-010-0367-5
– ident: ref34
  doi: 10.3324/haematol.11224
– ident: ref87
  doi: 10.1136/ard.62.7.686
– ident: ref120
  doi: 10.1016/j.jhep.2011.10.011
– ident: ref27
  doi: 10.1002/hep.22976
– ident: ref110
  doi: 10.1007/s00296-009-1202-2
– ident: ref11
  doi: 10.1007/s00277-009-0806-7
– ident: ref101
– ident: ref107
  doi: 10.1002/acr.21654
– ident: ref108
  doi: 10.1111/j.1365-2141.2010.08076.x
– ident: ref124
– ident: ref38
  doi: 10.1371/journal.pone.0092266
– ident: ref70
– ident: ref62
  doi: 10.1136/ard.2009.126532
– ident: ref30
  doi: 10.1055/s-2005-915644
– ident: ref15
  doi: 10.1038/nm1096-1104
– ident: ref64
  doi: 10.1136/annrheumdis-2011-200350
– ident: ref90
– ident: ref37
  doi: 10.1111/j.1537-2995.2010.03056.x
– ident: ref42
  doi: 10.1016/j.jhep.2008.01.023
– ident: ref100
  doi: 10.1111/1756-185X.12154
– ident: ref132
  doi: 10.1002/hep.23327
– ident: ref23
  doi: 10.1086/590968
– ident: ref26
  doi: 10.1002/hep.21513
– ident: ref18
  doi: 10.1002/hep.510310232
– ident: ref85
  doi: 10.1111/j.1346-8138.2011.01434.x
– ident: ref129
  doi: 10.4049/jimmunol.180.2.688
– ident: ref109
  doi: 10.1517/14740338.4.3.599
– ident: ref71
  doi: 10.2169/internalmedicine.37.519
– ident: ref72
  doi: 10.1016/j.jcv.2004.02.013
– reference: 18786966 - Rheumatology (Oxford). 2008 Nov;47(11):1732-3
– reference: 12239179 - Blood. 2002 Oct 1;100(7):2637-41
– reference: 23898372 - World J Hepatol. 2013 Jul 27;5(7):387-92
– reference: 24343455 - Clin Rheumatol. 2014 Apr;33(4):577-86
– reference: 8170985 - Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8
– reference: 19447932 - J Rheumatol. 2009 Jun;36(6):1188-94
– reference: 16831590 - Gastroenterology. 2006 Jul;131(1):59-68
– reference: 20166185 - J Med Virol. 2010 Apr;82(4):546-55
– reference: 20472596 - Ann Rheum Dis. 2010 Jul;69(7):1352-5
– reference: 10922071 - Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9203-8
– reference: 8837608 - Nat Med. 1996 Oct;2(10):1104-8
– reference: 22796807 - Dig Dis. 2012;30(4):408-14
– reference: 21944979 - Joint Bone Spine. 2012 Jan;79(1):100-1
– reference: 18521652 - Clin Rheumatol. 2008 Aug;27(8):1069-71
– reference: 21196589 - J Rheumatol. 2011 Jan;38(1):181-2
– reference: 20306568 - Eur J Gastroenterol Hepatol. 2010 Apr;22(4):494-9
– reference: 17673066 - Mayo Clin Proc. 2007 Aug;82(8):967-75
– reference: 11128108 - Haematologia (Budap). 2000;30(3):159-65
– reference: 22127282 - J Hepatol. 2012 Jun;56(6):1420-1
– reference: 20668905 - Mod Rheumatol. 2011 Feb;21(1):16-23
– reference: 9779869 - J Rheumatol. 1998 Oct;25(10):2037-8
– reference: 19797507 - J Rheumatol. 2009 Nov;36(11):2416-20
– reference: 24663387 - PLoS One. 2014;9(3):e92266
– reference: 22349880 - Clin Rheumatol. 2012 Jun;31(6):931-6
– reference: 20151975 - Br J Haematol. 2010 Apr;149(1):3-13
– reference: 21246383 - J Gastroenterol. 2011 Apr;46(4):556-64
– reference: 23935355 - Hippokratia. 2013 Jan;17(1):91-3
– reference: 9678685 - Intern Med. 1998 Jun;37(6):519-22
– reference: 19544079 - Int J Hematol. 2009 Jul;90(1):13-23
– reference: 22935442 - Clin Exp Rheumatol. 2013 Jan-Feb;31(1):25-30
– reference: 25381975 - Drug Dev Res. 2014 Nov;75 Suppl 1:S42-5
– reference: 23908927 - Western Pac Surveill Response J. 2012 Aug 03;3(3):69-75
– reference: 12551985 - J Virol. 2003 Feb;77(4):2469-76
– reference: 15144137 - Clin Exp Rheumatol. 2004 May-Jun;22(3):375-6
– reference: 18221983 - Semin Arthritis Rheum. 2008 Dec;38(3):208-17
– reference: 21528424 - Mod Rheumatol. 2011 Dec;21(6):621-7
– reference: 23399361 - Blood Transfus. 2013 Apr;11(2):281-8
– reference: 17256718 - Hepatology. 2007 Feb;45(2):507-39
– reference: 21540199 - Ann Rheum Dis. 2011 Jun;70(6):896-904
– reference: 9620351 - Hepatology. 1998 Jun;27(6):1736-42
– reference: 18314221 - J Hepatol. 2008 May;48(5):743-6
– reference: 18433400 - Liver Int. 2008 May;28(5):718-20
– reference: 20535784 - Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54
– reference: 24261752 - Mod Rheumatol. 2014 Jan;24(1):1-7
– reference: 25532827 - BMC Musculoskelet Disord. 2014;15:449
– reference: 20345703 - Liver Int. 2010 Sep;30(8):1241-2
– reference: 19941642 - Arthritis Res Ther. 2009;11(6):R179
– reference: 21686590 - BMJ Case Rep. 2009;2009:null
– reference: 22661417 - J Rheumatol. 2012 Jun;39(6):1292-3; author reply 1293
– reference: 16908487 - N Engl J Med. 2006 Sep 7;355(10):973-5
– reference: 19075267 - J Clin Oncol. 2009 Feb 1;27(4):605-11
– reference: 15044834 - Intervirology. 2004;47(1):32-40
– reference: 12150847 - Lancet Infect Dis. 2002 Aug;2(8):479-86
– reference: 16103976 - Semin Liver Dis. 2005;25 Suppl 1:3-8
– reference: 20444750 - Ann Rheum Dis. 2010 Jun;69(6):964-75
– reference: 20049753 - Hepatology. 2010 Feb;51(2):422-30
– reference: 15885351 - J Hepatol. 2005 Jun;42(6):813-9
– reference: 23749673 - Semin Liver Dis. 2013 May;33(2):167-77
– reference: 12810441 - Ann Rheum Dis. 2003 Jul;62(7):686-7
– reference: 19346146 - Joint Bone Spine. 2009 May;76(3):308-11
– reference: 21719446 - Ann Rheum Dis. 2011 Oct;70(10):1719-25
– reference: 20303674 - Pathol Biol (Paris). 2010 Aug;58(4):254-7
– reference: 19697028 - Ann Hematol. 2010 Mar;89(3):255-62
– reference: 8496385 - J Clin Pathol. 1993 Apr;46(4):304-8
– reference: 11187122 - N Engl J Med. 2001 Jan 4;344(1):68-9
– reference: 22273662 - Vaccine. 2012 Mar 9;30(12):2212-9
– reference: 18643758 - Clin Infect Dis. 2008 Sep 1;47(5):e52-6
– reference: 12757519 - Transfusion. 2003 Jun;43(6):696-704
– reference: 21807545 - Joint Bone Spine. 2011 Dec;78(6):653-4
– reference: 22077677 - J Dermatol. 2012 Mar;39(3):269-73
– reference: 10655275 - Hepatology. 2000 Feb;31(2):488-95
– reference: 19830433 - Rheumatol Int. 2011 Mar;31(3):403-4
– reference: 15934864 - Expert Opin Drug Saf. 2005 May;4(3):599-608
– reference: 22930597 - Ann Rheum Dis. 2013 Feb;72(2):308-10
– reference: 18766129 - J Clin Rheumatol. 2008 Aug;14(4):245-6
– reference: 23606869 - Clin Dev Immunol. 2013;2013:410521
– reference: 17256766 - Hepatology. 2007 Feb;45(2):277-85
– reference: 17894766 - Intern Med J. 2007 Oct;37(10):705-12
– reference: 25613809 - Hepatology. 2015 Jul;62(1):40-6
– reference: 21269234 - Expert Opin Biol Ther. 2011 Apr;11(4):533-44
– reference: 8574849 - Immunity. 1996 Jan;4(1):25-36
– reference: 19399803 - Hepatology. 2009 May;49(5 Suppl):S156-65
– reference: 11552064 - Transfusion. 2001 Sep;41(9):1093-9
– reference: 17112622 - J Hepatol. 2007 Jan;46(1):160-70
– reference: 15288614 - J Clin Virol. 2004 Sep;31(1):53-7
– reference: 22075282 - Eur J Intern Med. 2011 Dec;22(6):572-5
– reference: 16865308 - Clin Rheumatol. 2007 Jun;26(6):950-2
– reference: 18055990 - Haematologica. 2007 Dec;92(12):1664-70
– reference: 18203328 - J Rheumatol. 2008 Mar;35(3):421-4
– reference: 22544263 - Clin Rheumatol. 2012 Aug;31(8):1169-75
– reference: 21257300 - Curr Opin Immunol. 2011 Apr;23(2):237-43
– reference: 22033451 - Medicine (Baltimore). 2011 Nov;90(6):359-71
– reference: 21953336 - Ann Rheum Dis. 2012 Jan;71(1):4-12
– reference: 19399815 - Hepatology. 2009 May;49(5 Suppl):S22-7
– reference: 21626075 - Mod Rheumatol. 2011 Dec;21(6):701-5
– reference: 12858469 - J Rheumatol. 2003 Jul;30(7):1624-5
– reference: 21844146 - J Rheumatol. 2011 Oct;38(10):2209-14
– reference: 3006059 - Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31
– reference: 17596145 - Br J Dermatol. 2007 Sep;157(3):587-90
– reference: 18178805 - J Immunol. 2008 Jan 15;180(2):688-92
– reference: 18715666 - J Hepatol. 2008 Oct;49(4):652-7
– reference: 24397839 - Hepatol Res. 2014 Jan;44 Suppl S1:1-58
– reference: 20379839 - Clin Rheumatol. 2013 Mar;32 Suppl 1:S47-9
– reference: 24495663 - Eur J Intern Med. 2014 Jun;25(5):482-4
– reference: 18512708 - Arthritis Rheum. 2008 Jun 15;59(6):762-84
– reference: 21880218 - J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):285-9
– reference: 2306066 - Ann Intern Med. 1990 Mar 1;112(5):381-2
– reference: 19399812 - Hepatology. 2009 May;49(5 Suppl):S35-44
– reference: 24077913 - Clin Rheumatol. 2014 Jan;33(1):119-23
– reference: 18854348 - Rheumatology (Oxford). 2008 Dec;47(12):1838-40
– reference: 18173926 - Clin Exp Rheumatol. 2007 Nov-Dec;25(6):888-9
– reference: 24164839 - Int J Rheum Dis. 2013 Oct;16(5):527-31
– reference: 20837949 - J Clin Oncol. 2010 Dec 1;28(34):5097-100
– reference: 24698305 - Int J Rheum Dis. 2016 May;19(5):470-5
– reference: 10869298 - Hepatology. 2000 Jul;32(1):116-23
– reference: 19280622 - Hepatology. 2009 May;49(5):1503-14
– reference: 21901356 - Mod Rheumatol. 2012 Jun;22(3):470-3
– reference: 22686858 - Hepatol Res. 2012 Jul;42(7):627-36
– reference: 19561036 - Ann Oncol. 2009 Dec;20(12):2013-7
– reference: 23111095 - Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21
– reference: 21332731 - Transfusion. 2011 Aug;51(8):1840-6
– reference: 9826720 - Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14447-52
– reference: 16447285 - Hepatology. 2006 Feb;43(2 Suppl 1):S173-81
– reference: 17644391 - Joint Bone Spine. 2007 Oct;74(5):407-9
– reference: 1983820 - Gastroenterology. 1991 Jan;100(1):182-8
– reference: 11229464 - Arthritis Rheum. 2001 Feb;44(2):339-42
– reference: 20556450 - Clin Rheumatol. 2010 Sep;29(9):1021-9
– reference: 20931272 - Mod Rheumatol. 2011 Apr;21(2):215-8
– reference: 1962626 - Am J Gastroenterol. 1991 Dec;86(12):1804-8
– reference: 22392695 - Arthritis Care Res (Hoboken). 2012 Aug;64(8):1265-8
– reference: 10387938 - N Engl J Med. 1999 Jul 1;341(1):22-6
– reference: 23771951 - Rheumatology (Oxford). 2014 Jan;53(1):195-6
– reference: 16564573 - J Infect. 2007 Feb;54(2):185-91
– reference: 25114684 - Int J Rheumatol. 2014;2014:926836
– reference: 20008922 - J Rheumatol. 2010 Feb;37(2):346-50
SSID ssj0023352
Score 2.420267
SecondaryResourceType review_article
Snippet Accompanying the increased use of biological and non-biological antirheumatic drugs,a greater number of cases of hepatitis B virus(HBV) reactivation have been...
Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have...
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 10274
SubjectTerms Antirheumatic Agents - adverse effects
Antiviral Agents - therapeutic use
Hepatitis
Hepatitis B - diagnosis
Hepatitis B - epidemiology
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Humans
Immunocompromised Host
Prevalence
Recurrence
Rheumatic Diseases - diagnosis
Rheumatic Diseases - drug therapy
Rheumatic Diseases - epidemiology
Rheumatic Diseases - immunology
Risk Assessment
Risk Factors
therapy;Resolved
Topic Highlight
Virus Activation - drug effects
virus;Antirheumatic
Title Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations
URI http://lib.cqvip.com/qk/84123X/201536/90888889504849535154484852.html
https://www.ncbi.nlm.nih.gov/pubmed/26420955
https://www.proquest.com/docview/1718330996
https://pubmed.ncbi.nlm.nih.gov/PMC4579875
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKcuGCQLy6PGQkTpSUJI4TlxuLWFUrwQF2xZ6IHMdpU7bJksfy-PXMxEmabhcEtFJUxYnd-vsynUlmPhPyzBNMqlgzS-kksrwkEZZkQWIJL7GZFwQqThq1z_f-_MQ7OuWno9HnQdZSXUVT9fPKupL_QRX2Aa5YJfsPyPadwg74DPjCFhCG7V9hPNeYD12l5eRgcpEWNT4CwEIFc5t1Itup7zLMYRLTYqlro9JqKq8awacPmF9uFANymPYz-T3FruArr3W76FI59GJNBs5AdGIhy6rIUd6zMJpO2Ouno37drne5KWj_uKyzsv7Sk-mwXqU_5FqatnShq7xcpsM7EQ7HtIm2sls3FssF8wd7jP5SZ15NAXRLIzY0lg6GxFeZcZTEgbn_tlpML1xnmjJ_unMs_I7zdYMruHQuCult_tH6PMOu6Rq57kIY4XR3c9qAHOvNzJNuHPHlznioFN32gNIbyzxbfAWHYtuF2YlLLqfXDvyV41vkZhto0NeGNbfJSGd3yKpnDD2gDWPokDF0wxiKjKFbjKEtY15R5Au0xXTAF3qJL3fJyeHb4zdzq11tw1KexyrLYUwGGi5d15Wxy3Si7ERr24ltP4lsJWfw9h2hPBnEAcS9DpeRkIqziCmw5DN2j-xleaYfEMpinkiYQT7jKOcWCRW5joxsEcsYHegxedFPZnhuVFVCTLiDF54iMOmZo06U8AR3x8Tu5jtUrXI9LqByFkIEi8iFgFwIyIWAXNggNybP-1O6Af5w8NMOxBCMKz4xk5nO6zJ0wHNjDIIof0zuG1D77jpmjEmwBXd_AAq3b7dk6bIRcPd4MBMB3_9tnw_Jjc0F9ojsVUWtH4PzW0VPGgb_AkgWteo
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatitis+B+virus+reactivation+associated+with+antirheumatic+therapy%3A+Risk+and+prophylaxis+recommendations&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Mori%2C+Shunsuke&rft.au=Fujiyama%2C+Shigetoshi&rft.date=2015-09-28&rft.eissn=2219-2840&rft.volume=21&rft.issue=36&rft.spage=10274&rft_id=info:doi/10.3748%2Fwjg.v21.i36.10274&rft_id=info%3Apmid%2F26420955&rft.externalDocID=26420955
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg